KemPharm Analyst Ratings
KemPharm Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2022 | 81.16% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 99.28% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 81.16% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 117.39% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 407.25% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -72.83% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -54.71% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -80.98% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -45.65% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 207.97% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 99.28% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/17/2022 | 81.16% | HC Wainwright & Co. | 11 美元 → 10 美元 | 维护 | 买 |
| 01/31/2022 | 99.28% | HC Wainwright & Co. | 10 美元 → 11 美元 | 升级 | 中性 → 买入 |
| 2021 年 9 月 4 日 | 81.16% | HC Wainwright & Co. | 12 美元 → 10 美元 | 维护 | 中立 |
| 2021 年 4 月 3 日 | 117.39% | HC Wainwright & Co. | 24 美元 → 12 美元 | 降级 | 买入 → 中性 |
| 2021 年 1 月 25 日 | 407.25% | 罗斯资本 | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 05/20/2020 | -72.83% | HC Wainwright & Co. | 2.5 美元 → 1.5 美元 | 重申 | → 购买 |
| 2019 年 11 月 20 日 | -54.71% | HC Wainwright & Co. | $3 → 2.5 美元 | 重申 | → 购买 |
| 09/05/2019 | -80.98% | 罗斯资本 | 4.25 美元 → 1.05 美元 | 降级 | 买入 → 中性 |
| 06/19/2019 | -45.65% | HC Wainwright & Co. | → 3 美元 | 启动覆盖范围开启 | → 购买 |
| 05/23/2018 | 207.97% | 詹尼蒙哥马利斯科特 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 2018 年 2 月 26 日 | 99.28% | Canaccord Genu | 7 美元 → 11 美元 | 维护 | 买 |
KemPharm Questions & Answers
KempHarm 问题与解答
The latest price target for KemPharm (NASDAQ: KMPH) was reported by HC Wainwright & Co. on August 17, 2022. The analyst firm set a price target for $10.00 expecting KMPH to rise to within 12 months (a possible 81.16% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年8月17日公布了KempHarm（纳斯达克股票代码：KMPH）的最新目标股价。该分析公司将目标股价定为10.00美元，预计KMPH将在12个月内升至12个月内（可能上涨81.16％）。去年有两家分析公司公布了评级。
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by HC Wainwright & Co., and KemPharm maintained their buy rating.
HC Wainwright & Co. 对KempHarm（纳斯达克股票代码：KMPH）的最新分析师评级由HC Wainwright & Co. 提供，KempHarm维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on August 17, 2022 so you should expect the next rating to be made available sometime around August 17, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与KempHarm的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。KempHarm的最新评级是在2022年8月17日公布的，因此您应该预计下一个评级将在2023年8月17日左右公布。
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a maintained with a price target of $11.00 to $10.00. The current price KemPharm (KMPH) is trading at is $5.52, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的KempHarm（KMPH）评级保持不变，目标股价为11.00美元至10.00美元。KempHarm（KMPH）目前的交易价格为5.52美元，超出了分析师的预期区间。